Vivoryon Therapeutics
Biopharmaceutical company focused on the development of innovative small molecule drugs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | €15.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (111 %) | - | 783 % | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (118 %) | - | 783 % | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 162 % | - | (487 %) | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Vivoryon Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule-based medicines for the treatment of Alzheimer's disease and other neurodegenerative disorders. The company's therapeutic approach is centered on the inhibition of the enzyme glutaminyl cyclase (QC), which is involved in the formation of neurotoxic pyroglutamate-Abeta (pGlu-Abeta) oligomers. These oligomers are believed to be a key driver of Alzheimer's disease pathogenesis.
Vivoryon's lead product candidate, Varoglutamstat (PQ912), is an orally available QC inhibitor that has completed a Phase 2b clinical trial in patients with early Alzheimer's disease. The company is also developing a pipeline of other QC inhibitors for the treatment of other neurodegenerative disorders, as well as for other indications such as cancer and fibrosis.
Vivoryon's business model is focused on the development and commercialization of its product candidates. The company plans to partner with larger pharmaceutical companies to commercialize its products in major markets, while retaining commercialization rights in certain niche markets. Vivoryon's primary source of revenue is expected to be from milestone payments, royalties, and product sales.
Keywords: Alzheimer's disease, neurodegenerative disorders, glutaminyl cyclase, QC inhibitor, Varoglutamstat, PQ912, clinical-stage, biopharmaceutical, small molecules, pGlu-Abeta.